Hookipa Pharma Stock Fundamentals
| HOOK Stock | USD 1.23 0.02 1.65% |
Hookipa Pharma fundamentals help investors to digest information that contributes to Hookipa Pharma's financial success or failures. It also enables traders to predict the movement of Hookipa Stock. The fundamental analysis module provides a way to measure Hookipa Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hookipa Pharma stock.
At this time, Hookipa Pharma's Net Interest Income is quite stable compared to the past year. Interest Income is expected to rise to about 3.9 M this year, although the value of Interest Expense will most likely fall to 1,900.
Hookipa | Select Account or Indicator |
Hookipa Pharma Company Profit Margin Analysis
Hookipa Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Hookipa Pharma Profit Margin | (0.99) % |
Most of Hookipa Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hookipa Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Hookipa Pretax Profit Margin
Pretax Profit Margin |
|
At this time, Hookipa Pharma's Pretax Profit Margin is quite stable compared to the past year.
Based on the latest financial disclosure, Hookipa Pharma has a Profit Margin of -0.9899%. This is 91.17% lower than that of the Biotechnology sector and 95.7% lower than that of the Health Care industry. The profit margin for all United States stocks is 22.06% lower than that of the firm.
Hookipa Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hookipa Pharma's current stock value. Our valuation model uses many indicators to compare Hookipa Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hookipa Pharma competition to find correlations between indicators driving Hookipa Pharma's intrinsic value. More Info.Hookipa Pharma is rated below average in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . At this time, Hookipa Pharma's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Hookipa Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Hookipa Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hookipa Pharma from analyzing Hookipa Pharma's financial statements. These drivers represent accounts that assess Hookipa Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hookipa Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 288.8M | 76.5M | 53.1M | 76.6M | 25.2M | 23.9M | |
| Enterprise Value | 156.1M | 20.2M | (53.9M) | (34.0M) | (13.6M) | (12.9M) |
Hookipa Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (12.68) % | ||||
| Current Valuation | (24.22 M) | ||||
| Shares Outstanding | 9.66 M | ||||
| Shares Owned By Insiders | 2.00 % | ||||
| Shares Owned By Institutions | 58.65 % | ||||
| Number Of Shares Shorted | 84.09 K | ||||
| Price To Earning | 12.06 X | ||||
| Price To Book | 0.28 X | ||||
| Price To Sales | 0.33 X | ||||
| Revenue | 43.95 M | ||||
| Gross Profit | (23.19 M) | ||||
| EBITDA | (51.45 M) | ||||
| Net Income | (43.5 M) | ||||
| Cash And Equivalents | 117.92 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 875 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.48 X | ||||
| Book Value Per Share | 4.08 X | ||||
| Cash Flow From Operations | (76.98 M) | ||||
| Short Ratio | 1.21 X | ||||
| Earnings Per Share | (3.47) X | ||||
| Price To Earnings To Growth | (0.19) X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 14.59 M | ||||
| Total Asset | 82.55 M | ||||
| Retained Earnings | (412.76 M) | ||||
| Working Capital | 56.01 M | ||||
| Current Asset | 26.61 M | ||||
| Current Liabilities | 25.01 M | ||||
| Net Asset | 82.55 M |
About Hookipa Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hookipa Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hookipa Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hookipa Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.8 M | 8 M | |
| Total Revenue | 43.9 M | 46.1 M | |
| Cost Of Revenue | 3.2 M | 3 M | |
| Stock Based Compensation To Revenue | 0.12 | 0.13 | |
| Sales General And Administrative To Revenue | 1.06 | 1.18 | |
| Research And Ddevelopement To Revenue | 3.86 | 3.09 | |
| Capex To Revenue | 0.19 | 0.24 | |
| Revenue Per Share | 2.45 | 2.33 | |
| Ebit Per Revenue | (5.58) | (5.86) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Hookipa Pharma Piotroski F Score and Hookipa Pharma Altman Z Score analysis. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.47) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.